BioCentury
ARTICLE | Company News

Carbylan BioSurgery, Shanghai Jingfeng deal

December 3, 2012 8:00 AM UTC

Carbylan granted Shanghai Jingfeng exclusive Chinese rights to undisclosed patents and IP related to Carbylan's Hydros-TA technology. Carbylan received an undisclosed upfront payment and is eligible for development, regulatory and commercialization milestones. Shanghai Jingfeng will develop and commercialize Hydros-TA in China to treat pain in patients with osteoarthritis (OA) of the knee. Hydros-TA has completed a Phase II trial for the indication. Carbylan said the companies declined to disclose details. ...